Cite

HARVARD Citation

    Chua, H. et al. (n.d.). RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma. Hepatology. 62 (5), pp. 1480-1496. [Online]. 
  
Back to record